Correlation Between Skye Bioscience, and Protagonist Therapeutics

Can any of the company-specific risk be diversified away by investing in both Skye Bioscience, and Protagonist Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Skye Bioscience, and Protagonist Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Skye Bioscience, Common and Protagonist Therapeutics, you can compare the effects of market volatilities on Skye Bioscience, and Protagonist Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Skye Bioscience, with a short position of Protagonist Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Skye Bioscience, and Protagonist Therapeutics.

Diversification Opportunities for Skye Bioscience, and Protagonist Therapeutics

0.64

Correlation Coefficient

Skye Bioscience,  Protagonist Therapeutics

Poor diversification

The 3 months correlation between Skye and Protagonist is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Skye Bioscience, Common and Protagonist Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protagonist Therapeutics and Skye Bioscience, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Skye Bioscience, Common are associated (or correlated) with Protagonist Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protagonist Therapeutics has no effect on the direction of Skye Bioscience, i.e., Skye Bioscience, and Protagonist Therapeutics go up and down completely randomly.

Pair Corralation between Skye Bioscience, and Protagonist Therapeutics

Given the investment horizon of 90 days Skye Bioscience, Common is expected to under-perform the Protagonist Therapeutics. In addition to that, Skye Bioscience, is 1.78 times more volatile than Protagonist Therapeutics. It trades about -0.12 of its total potential returns per unit of risk. Protagonist Therapeutics is currently generating about -0.07 per unit of volatility. If you would invest  4,500  in Protagonist Therapeutics on September 30, 2024 and sell it today you would lose (604.00) from holding Protagonist Therapeutics or give up 13.42% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Skye Bioscience, Common  vs.  Protagonist Therapeutics

Skye Bioscience, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Skye Bioscience, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Protagonist Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's technical and fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Skye Bioscience, and Protagonist Therapeutics

The main advantage of trading using opposite Skye Bioscience, and Protagonist Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Skye Bioscience, position performs unexpectedly, Protagonist Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagonist Therapeutics will offset losses from the drop in Protagonist Therapeutics' long position.

The idea behind Skye Bioscience, Common and Protagonist Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.